| Q92177435 | A Guide to Investigating Suspected Outbreaks of Mucormycosis in Healthcare |
| Q38856520 | A Rare Cause of Massive Upper Gastrointestinal Hemorrhage in Immunocompromised Host |
| Q93384048 | A Survey of Infection in Allogenic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia |
| Q28535237 | A cell-free fluorometric high-throughput screen for inhibitors of Rtt109-catalyzed histone acetylation |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q35790217 | A consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections |
| Q43017233 | A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients |
| Q42222406 | A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning |
| Q46200207 | A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. |
| Q83919477 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients |
| Q40517539 | A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients |
| Q40287559 | A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children |
| Q53403788 | Abnormal conscious state and coma in transplant recipients. |
| Q80005615 | Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. May 1-4, 2004. Prague, Czech Republic |
| Q38133944 | Acremonium kiliense: case report and review of published studies |
| Q33188045 | Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q42271011 | Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry |
| Q26781064 | Adoptive T-cell therapy for fungal infections in haematology patients |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q35838440 | Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients |
| Q36774247 | Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders |
| Q43571175 | Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population |
| Q51018471 | Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients. |
| Q92076271 | Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP |
| Q46421810 | Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients |
| Q38858255 | An evaluation of invasive fungal sinusitis outcomes with subsite analysis and use of frozen section analysis |
| Q37128028 | An integrated genomic and transcriptomic survey of mucormycosis-causing fungi |
| Q35942379 | An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q34367333 | Antifungal and antihepatotoxic effects of sepia ink extract against oxidative stress as a risk factor of invasive pulmonary aspergillosis in neutropenic mice |
| Q42723597 | Antifungal drugs: predicting clinical efficacy with pharmacodynamics |
| Q37009912 | Antifungal management in cancer patients |
| Q36505508 | Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q37727168 | Antifungal prophylaxis and treatment in patients with hematological malignancies |
| Q36658236 | Antifungal prophylaxis following reduced-intensity stem cell transplantation |
| Q38223925 | Antifungal susceptibility profile of cryptic species of Aspergillus |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q36591360 | Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection |
| Q24239978 | Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections |
| Q24243629 | Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections |
| Q42016123 | Antimicrobial and free radical scavenging activities of five Palestinian medicinal plants |
| Q49425859 | Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis |
| Q37853604 | Approach to the neonate with ecchymoses and crusts |
| Q37772501 | Approaches to the early treatment of invasive fungal infection |
| Q44437808 | Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus |
| Q35038459 | Aspergillosis. Pathogenesis, clinical manifestations, and therapy |
| Q34637909 | Aspergillus fumigatus AcuM regulates both iron acquisition and gluconeogenesis |
| Q35045054 | Aspergillus fumigatus and related species |
| Q39950603 | Aspergillus fumigatus-induced interleukin-8 synthesis by respiratory epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 MAPK, and ERK1/2 pathways and not by the toll-like receptor-MyD88 pathway. |
| Q34131696 | Aspergillus fumigatus: contours of an opportunistic human pathogen |
| Q37702655 | Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid |
| Q35022494 | Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q31004718 | Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy |
| Q35793931 | Aspergillus ustus infections among transplant recipients |
| Q33859147 | Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species |
| Q40710446 | Association of mannose-binding lectin levels and invasive fungal disease in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic hematopoietic stem cell transplantation |
| Q91654934 | Atti Le giornate della ricerca scientificae delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Roma 20-21 dicembre 2019 |
| Q37312187 | Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis |
| Q35913870 | Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients |
| Q34718619 | Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus |
| Q42433042 | Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus |
| Q27333075 | Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides |
| Q36747015 | Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus |
| Q35784447 | Carbon assimilation profiles as a tool for identification of zygomycetes |
| Q40667837 | Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis |
| Q46653990 | Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. |
| Q40317065 | Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus |
| Q43198289 | Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study |
| Q37159584 | Caspofungin for treatment of invasive aspergillus infections. |
| Q54611603 | Central nervous system infections in transplantation. |
| Q36668077 | Changes of serum aspergillus galactomannan during hematopoietic stem cell transplantation in children with prior invasive aspergillosis |
| Q36920608 | Changing epidemiology of rare mould infections: implications for therapy |
| Q35678997 | Changing strategies for the management of invasive fungal infections |
| Q46240270 | Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species |
| Q28547946 | Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus |
| Q64086603 | Characterization of the putative polysaccharide synthase CpsA and its effects on the virulence of the human pathogen Aspergillus fumigatus |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q92678860 | Chronic Cavitary Pulmonary Aspergillosis: A Case Report and Review of the Literature |
| Q44851734 | Classification of invasive fungal disease in patients with acute myeloid leukaemia |
| Q35086478 | Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. |
| Q37157656 | Clinical and epidemiological aspects of infections caused by fusarium species: a collaborative study from Israel |
| Q38759809 | Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation |
| Q40351661 | Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation |
| Q36235068 | Clinical implications of environmental sources for Aspergillus |
| Q44217448 | Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi |
| Q35026481 | Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. |
| Q53167712 | Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies |
| Q51170048 | Clinical utility of a panfungal polymerase chain reaction assay for invasive fungal diseases in patients with haematologic disorders. |
| Q40052359 | Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. |
| Q37859378 | Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review. |
| Q81706307 | Combination of umbilical cord blood with BM from a 2-month-old sibling as lifesaving BMT for very severe aplastic anemia |
| Q37475959 | Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis |
| Q35974333 | Combination therapy for mucormycosis: why, what, and how? |
| Q34680675 | Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model |
| Q38609513 | Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole |
| Q35266270 | Comparison of histopathological analysis, culture and polymerase chain reaction assays to detect mucormycosis in biopsy and blood specimens |
| Q41671639 | Comparison of serum PCR assay and histopathology for the diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients with sinus involvement |
| Q34073470 | Comparison of six DNA extraction methods for recovery of fungal DNA as assessed by quantitative PCR. |
| Q36597796 | Comparison of the semisolid agar antifungal susceptibility test with the NCCLS M38-P broth microdilution test for screening of filamentous fungi |
| Q31141711 | Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis . |
| Q38479896 | Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. |
| Q46897118 | Computed tomography guided percutaneous lung biopsies and suspected fungal infections in pediatric cancer patients |
| Q38284463 | Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q33877277 | Construction of a Recyclable Genetic Marker and Serial Gene Deletions in the Human Pathogenic Mucorales Mucor circinelloides |
| Q37886974 | Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence |
| Q37562454 | Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis |
| Q41142605 | Could Histoplasma capsulatum Be Related to Healthcare-Associated Infections? |
| Q37201768 | Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America |
| Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
| Q37402524 | Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients |
| Q37628677 | Current status and future perspectives on molecular and serological methods in diagnostic mycology |
| Q36900157 | Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens |
| Q54109898 | Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. |
| Q36139494 | Cytokines and fungal infections |
| Q37401327 | D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections |
| Q43293528 | Deep, respiratory tract and ear infections caused by Pseudallescheria (Scedosporium) and Microascus (Scopulariopsis) in Finland. A 10-year retrospective multi-center study |
| Q46495013 | Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis |
| Q37833638 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies |
| Q35220840 | Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay |
| Q36957985 | Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis |
| Q41762716 | Development of a DNA microarray for detection and identification of fungal pathogens involved in invasive mycoses |
| Q40248979 | Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens |
| Q37463228 | Diagnosis and treatment of aspergillosis in children |
| Q37650317 | Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. |
| Q36862446 | Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). |
| Q47655061 | Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples |
| Q34514484 | Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis |
| Q36584898 | Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies |
| Q44368832 | Diagnostic value of the serum galactomannan assay for invasive aspergillosis: it is less useful in non-haematological patients. |
| Q51201410 | Differences in beta-glucan levels in culture supernatants of a variety of fungi. |
| Q35666612 | Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections |
| Q38165714 | Discovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study |
| Q34718528 | Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production |
| Q92298531 | Disseminated Mucormycosis with Extensive Cardiac Involvement |
| Q35184276 | Diverse and bioactive endophytic Aspergilli inhabit Cupressaceae plant family |
| Q35215827 | Diversity and significance of mold species in Norwegian drinking water |
| Q42954068 | Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? |
| Q45995163 | Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. |
| Q46095416 | Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients |
| Q39634880 | Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation |
| Q41985252 | EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model |
| Q33843670 | ERG11 Gene Mutations and MDR1 Upregulation Confer Pan-Azole Resistance in Candida tropicalis Causing Disseminated Candidiasis in an Acute Lymphoblastic Leukemia Patient on Posaconazole Prophylaxis |
| Q30433397 | Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis |
| Q46836740 | Early clinical experience with anidulafungin at a large tertiary care medical center |
| Q80168014 | Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation |
| Q44579673 | Early pneumonia after allogenic stem cell transplantation |
| Q28262565 | Echinocandins in the management of invasive fungal infections, part 1 |
| Q37475459 | Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? |
| Q37936259 | Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies |
| Q34013416 | Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands |
| Q46661645 | Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). |
| Q34509692 | Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus |
| Q38861365 | Efficacy and safety of itraconazole use in infants |
| Q53271427 | Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT. |
| Q34298803 | Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis |
| Q35215384 | Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans |
| Q36341374 | Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients |
| Q44560495 | Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection |
| Q34635418 | Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study |
| Q36969836 | Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis |
| Q51166051 | Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection. |
| Q35270948 | Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis |
| Q31161843 | Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys |
| Q38261282 | Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole |
| Q79300228 | Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q36199785 | Emerging fungal diseases |
| Q35161571 | Emerging fungal infections in immunocompromised patients |
| Q35587146 | Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients |
| Q37889387 | Emerging moulds: epidemiological trends and antifungal resistance |
| Q41928964 | Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies |
| Q27320054 | Environmental dimensionality controls the interaction of phagocytes with the pathogenic fungi Aspergillus fumigatus and Candida albicans |
| Q33768795 | Enzymatic treatment of specimens before DNA extraction directly influences molecular detection of infectious agents |
| Q37864427 | Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature |
| Q37668719 | Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies |
| Q45938423 | Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. |
| Q34440240 | Epidemiology and outcome of zygomycosis: a review of 929 reported cases |
| Q35089772 | Epidemiology and treatment approaches in management of invasive fungal infections |
| Q35131913 | Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q37327072 | Epidemiology of invasive fungal infection |
| Q53175359 | Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. |
| Q37788797 | Epidemiology of invasive fungal infections in neonates and children |
| Q28293483 | Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation |
| Q36876327 | Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. |
| Q83781690 | Ethmoiditis-associated apex syndrome may result in temporary blindness after allo-SCT |
| Q36714507 | Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies |
| Q41812477 | Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi |
| Q34509838 | Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method |
| Q90637532 | Evaluation of molecular identification of Aspergillus species causing fungal keratitis |
| Q41361550 | Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi |
| Q37761047 | Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma |
| Q46736783 | Expression of Aspergillus fumigatus virulence-related genes detected in vitro and in vivo with competitive RT-PCR. |
| Q35647730 | Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus |
| Q99418176 | Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan |
| Q33867013 | Factors associated with mortality in transplant patients with invasive aspergillosis |
| Q37123565 | Febrile neutropenia in children with acute lymphoblastic leukemia: single center experience |
| Q46362922 | Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. |
| Q47882912 | Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies |
| Q43223060 | Forty-one recent cases of invasive zygomycosis from a global clinical registry. |
| Q91823237 | Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis |
| Q90603852 | Fosmanogepix (APX001) is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus |
| Q34492766 | Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus |
| Q36278069 | Fungal CNS infections in patients with hematologic malignancy. |
| Q45917612 | Fungal biomass is a key factor affecting polymorphonuclear leucocyte-induced hyphal damage of filamentous fungi. |
| Q35579273 | Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients. |
| Q34153565 | Fungal diagnostics in pneumonia |
| Q37053622 | Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. |
| Q46808698 | Fungal infections after haematology unit renovation: evidence of clinical, environmental and economical impact |
| Q38202571 | Fungal infections in cancer patients |
| Q35038473 | Fungal infections in nontransplant patients with hematologic malignancies |
| Q51184875 | Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. |
| Q36382578 | Fungal infections in solid organ transplantation |
| Q33896940 | Fungal infections in transplant and oncology patients |
| Q36768045 | Fungal infections of the CNS: treatment strategies for the immunocompromised patient |
| Q36206568 | Fungal infections: their diagnosis and treatment in transplant recipients |
| Q21090534 | Fungal invasion of normally non-phagocytic host cells |
| Q40646892 | Fungal meningitis caused by Lomentospora prolificans after allogeneic hematopoietic stem cell transplantation |
| Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
| Q37971025 | Fungal surface and innate immune recognition of filamentous fungi |
| Q45054608 | Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. |
| Q44883924 | Fusarium infection in hematopoietic stem cell transplant recipients |
| Q37114436 | Fusarium infection in lung transplant patients: report of 6 cases and review of the literature |
| Q33614273 | Fusarium proliferatum soft tissue infection at the site of a puncture by a plant: recovery, isolation, and direct molecular identification |
| Q59308866 | Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies |
| Q40497134 | Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study |
| Q24186895 | Galactomannan detection for invasive aspergillosis in immunocompromised patients |
| Q24240734 | Galactomannan detection for invasive aspergillosis in immunocompromized patients |
| Q41917709 | Gastrointestinal mucormycosis: an evolving disease. |
| Q40470166 | Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. |
| Q35027380 | Genetic diversity among clinical isolates of Acremonium strictum determined during an investigation of a fatal mycosis |
| Q34431828 | Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism |
| Q90685718 | Genetic tools for investigating Mucorales fungal pathogenesis |
| Q27316191 | Genotyping bacterial and fungal pathogens using sequence variation in the gene for the CCA-adding enzyme |
| Q40454827 | Genus- and Species-Specific PCR Detection Methods. |
| Q34505388 | Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation |
| Q35599856 | Glucocorticoids and invasive fungal infections |
| Q38907111 | Granulocyte transfusions in the management of invasive fungal infections. |
| Q42838532 | Graphium basitruncatum fungemia in an immunosuppressed child post stem-cell transplantation. |
| Q28388806 | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective |
| Q37078261 | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide |
| Q46415258 | Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. |
| Q42087721 | Hard palate perforation in acute lymphoblastic leukemia due to mucormycosis - a case report |
| Q36823712 | Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections |
| Q51186226 | High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. |
| Q34026290 | Highly recombinant VGII Cryptococcus gattii population develops clonal outbreak clusters through both sexual macroevolution and asexual microevolution |
| Q30429049 | Hospital epidemiology and infection control in acute-care settings |
| Q35175555 | Host cell invasion in mucormycosis: role of iron |
| Q38245340 | Host-iron assimilation: pathogenesis and novel therapies of mucormycosis |
| Q35568846 | How to treat fungal infections in ICU patients |
| Q43995112 | IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. |
| Q92156315 | Identification of Candida spp. isolated from oral mucosa in patients with leukemias and lymphomas in Iran |
| Q41444940 | Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. |
| Q37373457 | Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients |
| Q37186705 | Immunocompromised hosts: immunopharmacology of modern antifungals. |
| Q37788693 | Immunogenetics of invasive aspergillosis |
| Q35076852 | Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients |
| Q35587105 | Impact of diagnostic markers on early antifungal therapy |
| Q42172303 | Impact of zygomycosis on microbiology workload: a survey study in Spain |
| Q43111893 | Impaired ribosome biogenesis disrupts the integration between morphogenesis and nuclear duplication during the germination of Aspergillus fumigatus. |
| Q36047931 | In Vitro Activities of Three Licensed Antifungal Agents against Spanish Clinical Isolates of Aspergillus spp |
| Q36672181 | In search of the holy grail of antifungal therapy |
| Q42111761 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing |
| Q37734590 | In vitro activity of anidulafungin against selected clinically important mold isolates |
| Q35870651 | In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection |
| Q42084568 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species |
| Q38984590 | In vitro evaluation of combination of polyenes with EDTA against Aspergillus spp. by different methods (FICI and CI Model). |
| Q37625139 | In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients |
| Q44429038 | In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs |
| Q41475716 | In-hospital transfer is a risk factor for invasive filamentous fungal infection among hospitalized patients with hematological malignancies: a matched case-control study |
| Q52714937 | In-patient outcomes of Hematopoietic Stem Cell Transplantation in Patients with Immune Mediated Inflammatory Diseases: A Nationwide Study. |
| Q98162350 | Inactivation of fungal spores in water using ozone: Kinetics, influencing factors and mechanisms |
| Q43533894 | Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience |
| Q46663951 | Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program |
| Q44049737 | Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation |
| Q40409590 | Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. |
| Q33644747 | Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. |
| Q37622117 | Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients |
| Q35622021 | Infections caused by Fusarium species |
| Q24657691 | Infections caused by Scedosporium spp. |
| Q45015455 | Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases |
| Q45198277 | Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome |
| Q36038899 | Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors |
| Q26859275 | Infections in myelodysplastic syndromes |
| Q80584979 | Infliximab for GVHD therapy in children |
| Q35821259 | Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties |
| Q40449192 | Integrin Cross-Talk Regulates the Human Neutrophil Response to Fungal β-Glucan in the Context of the Extracellular Matrix: A Prominent Role for VLA3 in the Antifungal Response. |
| Q64075877 | Invasive Fungal Infections While on Voriconazole, Liposomal Amphotericin B, or Micafungin for Antifungal Prophylaxis in Pediatric Stem Cell Transplant Patients |
| Q38205729 | Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review |
| Q40874890 | Invasive aspergillosis before HCT: safe to proceed? |
| Q42206933 | Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy |
| Q37854719 | Invasive aspergillosis in children with hematological malignancies |
| Q37854721 | Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation |
| Q35616161 | Invasive aspergillosis in patients with hematologic malignancies. |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q37983464 | Invasive aspergillosis: resistance to antifungal drugs |
| Q45018793 | Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey |
| Q59132031 | Invasive fungal infection by in immunocompetent hosts: A case series and literature review |
| Q37431764 | Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint |
| Q35719482 | Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance |
| Q41480974 | Invasive fungal infections in pediatric hematopoietic stem cell transplant patients |
| Q58376545 | Invasive fungal sinusitis: An effective combined treatment in five haematological patients |
| Q37428946 | Invasive mold infections: recent advances in management approaches |
| Q35848794 | Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. |
| Q47930062 | Invasive pulmonary aspergillosis in neutropenic patients and the influence of hospital renovation |
| Q40489747 | Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. |
| Q37315227 | Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment |
| Q39684037 | Isavuconazole therapy protects immunosuppressed mice from mucormycosis |
| Q38644817 | Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent |
| Q34900399 | Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections |
| Q44606439 | Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants |
| Q35011464 | Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates |
| Q35763847 | Levels of total fungus and Aspergillus on a pediatric hematopoietic stem cell transplant unit |
| Q38149379 | Life-threatening infection in transplant recipients |
| Q34108585 | Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections |
| Q28298468 | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) |
| Q36722703 | Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy |
| Q37202860 | Management of fungal infections following allogeneic stem cell transplantation |
| Q35675979 | Management of infectious complications in the hematopoietic stem cell transplant recipient |
| Q36286439 | Management of intracranial fungal infections in patients with haematological malignancies |
| Q53614688 | Medicolegal Implications of Nosocomial Infections: A Case Report of Aspergillus Contamination during Cardiac Surgery. |
| Q92180354 | Micafungin as antifungal prophylaxis in non-transplanted haemotological patients |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q36140652 | Micafungin: the US perspective |
| Q90319016 | Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease |
| Q40065410 | Molecular Characterization, Structural Modeling, and Evaluation of Antimicrobial Activity of Basrai Thaumatin-Like Protein against Fungal Infection. |
| Q46834709 | Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India |
| Q39887192 | Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. |
| Q34430706 | Molecular identification of zygomycetes from culture and experimentally infected tissues |
| Q23909611 | Monoclonal antibodies to hyphal exoantigens derived from the opportunistic pathogen, Aspergillus terreus |
| Q38919115 | Mucormycosis at a tertiary care centre in Gujarat, India |
| Q37534298 | Mucormycosis in immunochallenged patients |
| Q91747616 | Mucormycosis of the Central Nervous System |
| Q53490351 | Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. |
| Q24603297 | Mucormycosis, pseudallescheriasis, and other uncommon mold infections |
| Q42432176 | Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin |
| Q61758327 | Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis |
| Q30993609 | Multilocus DNA sequence comparisons rapidly identify pathogenic molds |
| Q36310961 | Mycological Microscopic and Culture Examination of 400 Bronchoalveolar Lavage (BAL) Samples. |
| Q41850594 | Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan |
| Q50195666 | Necrotizing fungal gingivitis in a patient with Acute Myelogenous Leukemia: visible yet obscure |
| Q56518068 | Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China |
| Q35561985 | New approaches to invasive fungal infections |
| Q34328907 | New strategy for rapid diagnosis and characterization of fungal infections: the example of corneal scrapings |
| Q35116820 | Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients |
| Q36741491 | Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients |
| Q53626853 | Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q36825717 | Nosocomial fungal infections: epidemiology, diagnosis, and treatment |
| Q37734691 | Novel inhalational murine model of invasive pulmonary aspergillosis |
| Q24530554 | Novel perspectives on mucormycosis: pathophysiology, presentation, and management |
| Q48149245 | Omics for Investigating Chitosan as an Antifungal and Gene Modulator |
| Q37873399 | Opportunistic invasive fungal pathogen Macrophomina phaseolina prognosis from immunocompromised humans to potential mitogenic RBL with an exceptional and novel antitumor and cytotoxic effect. |
| Q51190403 | Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. |
| Q38363105 | Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies |
| Q42645346 | Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations |
| Q37333687 | Outbreak of intestinal infection due to Rhizopus microsporus. |
| Q35584615 | Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles |
| Q33723583 | Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 |
| Q35588822 | PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue |
| Q90696193 | PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis |
| Q37976046 | Pathogenesis of mucormycosis |
| Q92106852 | Pathogenic Fungal Infection in the Lung |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q41211347 | Performance of lateral flow device and galactomannan for the detection of Aspergillus species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. |
| Q34154790 | Persistence versus escape: Aspergillus terreus and Aspergillus fumigatus employ different strategies during interactions with macrophages |
| Q34352109 | Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis |
| Q35959476 | Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature |
| Q33654022 | Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics |
| Q37389541 | Pinpointing prognostic indicators of fungal infections in transplant patients |
| Q54346717 | Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. |
| Q26827758 | Pneumonia in the neutropenic cancer patient |
| Q36086911 | Polarized response of endothelial cells to invasion by Aspergillus fumigatus |
| Q33392206 | Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies |
| Q34301611 | Posaconazole as salvage therapy for zygomycosis |
| Q37052755 | Posaconazole in the management of refractory invasive fungal infections |
| Q40413232 | Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation |
| Q43756553 | Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. |
| Q38237895 | Posaconazole salvage treatment for invasive fungal infection |
| Q37404840 | Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update |
| Q36828159 | Posaconazole: a new broad-spectrum antifungal agent |
| Q33382991 | Posaconazole: a new oral antifungal agent with an expanded spectrum of activity |
| Q40344144 | Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
| Q57569130 | Post-surgical invasive aspergillosis: An uncommon and under-appreciated entity |
| Q36150841 | Posttraumatic mucormycosis: a nationwide study in France and review of the literature |
| Q86518784 | Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients |
| Q36681043 | Predisposing Factors for Mucormycosis in Patients with Diabetes Mellitus; An Experience of 21 Years in Southern Iran |
| Q35180217 | Preliminary study of the fungal ecology at the haematology and medical-oncology ward in Bamako, Mali |
| Q37621550 | Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts |
| Q54578659 | Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. |
| Q40157268 | Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. |
| Q40324756 | Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia. |
| Q46645474 | Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis |
| Q40306219 | Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. |
| Q54723179 | Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematolog |
| Q42270167 | Protein kinase A regulatory subunit isoforms regulate growth and differentiation in Mucor circinelloides: essential role of PKAR4. |
| Q36278064 | Pseudallescheriasis in the 21st century |
| Q40415825 | Pulmonary mucormycosis mimicking as pulmonary tuberculosis: a case report |
| Q38296370 | Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. |
| Q43146785 | Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. |
| Q36539892 | Rapid detection of triazole antifungal resistance in Aspergillus fumigatus |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q37288342 | Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant |
| Q49168543 | Reactivity of the 1,3-β-D-glucan assay during bacteraemia: limited evidence from a prospective study |
| Q35638993 | Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis. |
| Q35821280 | Recent Advances in the Use of Drosophila melanogaster as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi |
| Q35917383 | Recent advances in antifungal pharmacotherapy for invasive fungal infections |
| Q24642450 | Recent advances in the management of mucormycosis: from bench to bedside |
| Q34161213 | Recent advances in the treatment of mucormycosis |
| Q37377752 | Recent approaches to antifungal therapy for invasive mycoses. |
| Q41929675 | Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. |
| Q58477139 | Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp |
| Q37380958 | Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) |
| Q40475150 | Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution. |
| Q34190284 | Regulatory circuitry governing fungal development, drug resistance, and disease. |
| Q38609462 | Repetitive-sequence-based PCR using the DiversiLab system for identification of Aspergillus species |
| Q43609178 | Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI) |
| Q37702451 | Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA). |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q37055215 | Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent |
| Q38017577 | Rhino-orbital-cerebral mucormycosis |
| Q40357629 | Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients. |
| Q36540732 | Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. |
| Q46077878 | Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients |
| Q40514264 | Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies |
| Q37327082 | Risk factors for invasive fungal infections in haematopoietic stem cell transplantation |
| Q37359336 | Risk factors for mortality in patients with invasive mucormycosis |
| Q39785801 | Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia |
| Q38950315 | Risk stratification and immunogenetic risk for infections following stem cell transplantation |
| Q53664706 | Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. |
| Q73256320 | Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning |
| Q36990751 | Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients |
| Q36689483 | Role of mini-host models in the study of medically important fungi. |
| Q42164508 | Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia |
| Q39215244 | Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections |
| Q35799730 | Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients |
| Q33863298 | Safety and efficacy of activated transfected killer cells for neutropenic fungal infections |
| Q36655030 | Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. |
| Q35622016 | Scedosporium species infections and treatments |
| Q51735777 | Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. |
| Q51047839 | Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. |
| Q41144399 | Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis |
| Q44006168 | Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies |
| Q38793633 | Skin lesion in a patient with acute myeloid leukemia |
| Q24594468 | Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus) |
| Q35200641 | Specific infectious complications after stem cell transplantation |
| Q27349560 | Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides |
| Q52145216 | Stem cell transplantation for acute myeloid leukemia with pulmonary and cerebral mucormycosis. |
| Q43604106 | Successful treatment of disseminated mixed invasive fungal infection after hematopoietic stem cell transplantation for severe aplastic anemia. |
| Q47230940 | Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation |
| Q37706814 | Successful treatment of periodontal mucormycosis: report of a case and literature review |
| Q34572967 | Sudden death in a patient with bone marrow transplant by a fungus among us |
| Q36049495 | Suppression of epithelial signal transducer and activator of transcription 1 activation by extracts of Aspergillus fumigatus |
| Q41951137 | Surfactant protein D binding to Aspergillus fumigatus hyphae is calcineurin-sensitive |
| Q42722136 | Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation |
| Q35585219 | Systemic Antifungal Therapy: New Options, New Challenges |
| Q43194195 | TLR polymorphisms and the risk of invasive fungal infections |
| Q37212562 | The Aspergillus fumigatus transcription factor Ace2 governs pigment production, conidiation and virulence. |
| Q64236059 | The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses? |
| Q35196866 | The application of laser microdissection in molecular detection and identification of aspergillus fumigatus from murine model of acute invasive pulmonary aspergillosis |
| Q36289060 | The changing face of fungal infections in health care settings |
| Q35185757 | The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy |
| Q36828156 | The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety |
| Q54622007 | The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. |
| Q34017347 | The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis |
| Q36139489 | The immune response to fungal infections |
| Q38199674 | The impact of antifungals on toll-like receptors |
| Q35960985 | The iron chelator deferasirox protects mice from mucormycosis through iron starvation |
| Q40319358 | The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis. |
| Q53085366 | The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? |
| Q79300230 | The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida |
| Q33364468 | The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation |
| Q44703748 | The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer |
| Q35193749 | The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. |
| Q38508539 | The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients |
| Q57100482 | The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration |
| Q37800610 | The value of amphotericin B in the treatment of invasive fungal infections |
| Q38526795 | Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. |
| Q37130676 | Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation |
| Q38984025 | Topographical and physiological differences of the skin mycobiome in health and disease |
| Q58694422 | Tracheobronchial manifestations of Aspergillus infections |
| Q40180378 | Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population |
| Q35573265 | Treatment of opportunistic mycoses: how long is long enough? |
| Q37863921 | Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? |
| Q33629045 | Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000-2013. |
| Q57569380 | Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients |
| Q36802717 | Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature |
| Q37910256 | Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment |
| Q35782575 | Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. |
| Q38152678 | Update on mucormycosis pathogenesis |
| Q38536076 | Update on the treatment of disseminated fusariosis: Focus on voriconazole. |
| Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
| Q40133093 | Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi |
| Q42911728 | Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiary-care center over a 12-month period |
| Q37810083 | Use of posaconazole in the treatment of invasive fungal infections |
| Q47700700 | Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis |
| Q35951605 | Utility of Aspergillus antigen detection in specimens other than serum specimens |
| Q38089915 | Utility of galactomannan antigen detection in bronchoalveolar lavage fluid in immunocompromised patients |
| Q35587108 | Utility of mould susceptibility testing |
| Q41000467 | VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection |
| Q53139996 | Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation. |
| Q44417870 | Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections |
| Q38073201 | Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review |
| Q37810091 | Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections |
| Q35069136 | Voriconazole: a new triazole antifungal agent |
| Q42148730 | What are fungal infections? |
| Q41860895 | Why is biopsy of suspected fungal lung lesions necessary? |
| Q45945768 | Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). |
| Q36774266 | Zygomycosis--current epidemiological aspects |
| Q36333225 | Zygomycosis: an emerging fungal infection |
| Q36433729 | Zygomycosis: the re-emerging fungal infection |
| Q81307340 | [Advances and limitations in the early diagnosis of invasive yeast infections] |
| Q99563193 | [Non-aspergillus molds infection after allogeneic stem cell transplantation: clinical analysis of 24 cases and outcomes] |
| Q83656563 | [Why might micafungin be the drug of choice in pediatric patients?] |